JP2024513999A5 - - Google Patents
Info
- Publication number
- JP2024513999A5 JP2024513999A5 JP2023563063A JP2023563063A JP2024513999A5 JP 2024513999 A5 JP2024513999 A5 JP 2024513999A5 JP 2023563063 A JP2023563063 A JP 2023563063A JP 2023563063 A JP2023563063 A JP 2023563063A JP 2024513999 A5 JP2024513999 A5 JP 2024513999A5
- Authority
- JP
- Japan
- Prior art keywords
- mrna
- vaccine according
- respiratory viral
- antigenic polypeptide
- encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163175007P | 2021-04-14 | 2021-04-14 | |
| US63/175,007 | 2021-04-14 | ||
| US202163242346P | 2021-09-09 | 2021-09-09 | |
| US63/242,346 | 2021-09-09 | ||
| PCT/US2022/024669 WO2022221440A1 (en) | 2021-04-14 | 2022-04-13 | Influenza-coronavirus combination vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513999A JP2024513999A (ja) | 2024-03-27 |
| JP2024513999A5 true JP2024513999A5 (cg-RX-API-DMAC10.html) | 2025-04-21 |
Family
ID=81579694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563063A Pending JP2024513999A (ja) | 2021-04-14 | 2022-04-13 | インフルエンザ-コロナウイルス組み合わせワクチン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240226277A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4322994A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024513999A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022258463A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022221440A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| EP3328394A4 (en) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| DE20164728T1 (de) | 2015-10-22 | 2021-09-30 | Modernatx, Inc. | Impfstoffe gegen atemwegsvirus |
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| SG11201901941YA (en) | 2016-09-14 | 2019-04-29 | Modernatx Inc | High purity rna compositions and methods for preparation thereof |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| EP3668977A4 (en) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | HPLC ANALYTICAL PROCESSES |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| MX2021010075A (es) | 2019-02-20 | 2021-12-10 | Modernatx Inc | Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales. |
| MX2021011031A (es) | 2019-03-11 | 2021-12-10 | Modernatx Inc | Proceso de transcripción in vitro en lotes alimentados. |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| WO2022150717A1 (en) | 2021-01-11 | 2022-07-14 | Modernatx, Inc. | Seasonal rna influenza virus vaccines |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| EP4604995A1 (en) * | 2022-10-17 | 2025-08-27 | BioNTech SE | Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection |
| KR20260021825A (ko) * | 2023-05-10 | 2026-02-13 | 세퀴러스 인코포레이티드 | 복합 백신 |
| US20260083835A1 (en) * | 2024-09-25 | 2026-03-26 | The Catholic University Of America | Modular bacteriophage t4 nanoparticle platform enables rapid design of dual covid-19-flu mucosal vaccines |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE291925T1 (de) | 2001-06-05 | 2005-04-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| JP2010531640A (ja) | 2007-06-29 | 2010-09-30 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション | 毒性化合物の分解方法 |
| DK2205618T3 (en) | 2007-09-26 | 2017-02-20 | Intrexon Corp | SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION |
| SG10201408164XA (en) | 2007-12-11 | 2015-01-29 | Scripps Research Inst | Compositions and methods related to mrna translational enhancer elements |
| KR20220025112A (ko) | 2011-06-08 | 2022-03-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
| EA201492055A1 (ru) | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
| ES2967701T3 (es) | 2013-03-15 | 2024-05-03 | Translate Bio Inc | Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas |
| SG10201801428RA (en) | 2013-08-21 | 2018-03-28 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| AU2014375402B2 (en) | 2013-12-30 | 2020-10-01 | CureVac SE | Artificial nucleic acid molecules |
| DE20164728T1 (de) * | 2015-10-22 | 2021-09-30 | Modernatx, Inc. | Impfstoffe gegen atemwegsvirus |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| MX2021010075A (es) | 2019-02-20 | 2021-12-10 | Modernatx Inc | Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales. |
| JP2023527175A (ja) * | 2020-05-21 | 2023-06-27 | ヴァクセス・テクノロジーズ,インコーポレーテッド | ワクチン放出のための組成物およびデバイスならびにそれらの使用 |
| WO2021239880A1 (en) * | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| GB2596820A (en) * | 2020-07-07 | 2022-01-12 | Spicona Inc | Combination vaccine |
| CN112546211A (zh) * | 2020-10-23 | 2021-03-26 | 嘉晨西海(杭州)生物技术有限公司 | 基于mRNA的针对冠状病毒和流感病毒的联合疫苗及其制备方法 |
-
2022
- 2022-04-13 EP EP22720863.4A patent/EP4322994A1/en active Pending
- 2022-04-13 WO PCT/US2022/024669 patent/WO2022221440A1/en not_active Ceased
- 2022-04-13 JP JP2023563063A patent/JP2024513999A/ja active Pending
- 2022-04-13 AU AU2022258463A patent/AU2022258463A1/en active Pending
- 2022-04-13 US US18/555,130 patent/US20240226277A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024514182A5 (cg-RX-API-DMAC10.html) | ||
| Serradell et al. | Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins | |
| JP5331340B2 (ja) | インフルエンザウィルスワクチン組成物、及びその使用方法 | |
| JP7817257B2 (ja) | mRNAワクチンを送達するための脂質ナノ粒子 | |
| TW202233232A (zh) | 遞送mRNA疫苗的脂質奈米顆粒 | |
| JP2024503698A5 (cg-RX-API-DMAC10.html) | ||
| Wohlbold et al. | Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice | |
| US6780421B1 (en) | Adjuvant for a vaccine composition | |
| Garçon et al. | Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach | |
| JP2011504486A5 (cg-RX-API-DMAC10.html) | ||
| Gupta et al. | A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases | |
| Ibañez et al. | M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A | |
| JP6185548B2 (ja) | インフルエンザワクチンの製造方法 | |
| JP2009539965A5 (cg-RX-API-DMAC10.html) | ||
| JP2017035093A5 (cg-RX-API-DMAC10.html) | ||
| Fotouhi et al. | Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus | |
| TW201427686A (zh) | 改良之疫苗組成物及使用方法 | |
| Lau et al. | The contribution of systemic and pulmonary immune effectors to vaccine-induced protection from H5N1 influenza virus infection | |
| JP2015500854A5 (cg-RX-API-DMAC10.html) | ||
| JP2009514839A5 (cg-RX-API-DMAC10.html) | ||
| Chaparian et al. | A virion-based combination vaccine protects against influenza and SARS-CoV-2 disease in mice | |
| JP2024015475A (ja) | コロナウイルスワクチン | |
| JP2024150687A (ja) | アジュバントおよび該アジュバントを含むワクチン | |
| Zhang et al. | DNA-based influenza vaccines as immunoprophylactic agents toward universality | |
| Lim et al. | RNA-dependent assembly of chimeric antigen nanoparticles as an efficient H5N1 pre-pandemic vaccine platform |